{"protocolSection": {"identificationModule": {"nctId": "NCT02056626", "orgStudyIdInfo": {"id": "5R01HL105520", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/5R01HL105520"}, "organization": {"fullName": "University of Rochester", "class": "OTHER"}, "briefTitle": "Conditioned Pharmacotherapeutic Effects in Hypertension", "officialTitle": "Conditioned Pharmacotherapeutic Effects in Hypertension"}, "statusModule": {"statusVerifiedDate": "2019-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-03"}, "primaryCompletionDateStruct": {"date": "2018-11-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-12-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-02-04", "studyFirstSubmitQcDate": "2014-02-05", "studyFirstPostDateStruct": {"date": "2014-02-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-05-23", "resultsFirstSubmitQcDate": "2019-05-23", "resultsFirstPostDateStruct": {"date": "2019-06-13", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-06-26", "lastUpdatePostDateStruct": {"date": "2019-07-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "John Bisognano", "investigatorTitle": "M.D., Ph.D", "investigatorAffiliation": "University of Rochester"}, "leadSponsor": {"name": "University of Rochester", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The proposed research is designed to determine if the application of classical conditioning operations could influence the clinical effects of a regimen of antihypertensive drug therapy. It will be determined if, capitalizing on conditioned pharmacotherapeutic effects, patients can be effectively treated with smaller cumulative amounts of drug.", "detailedDescription": "The proposed research is designed to determine if the application of classical conditioning operations could influence the clinical effects of a regimen of antihypertensive drug therapy. In a double-blind, randomized, parallel-controlled clinical trial, It will be determined if, capitalizing on conditioned pharmacotherapeutic effects, patients can be effectively treated with smaller cumulative amounts of drug. To this end, some hypertensive patients will be treated on a partial rather than a continuous schedule of pharmacologic reinforcement. These patients will be compared to: (a) patients who continue to be treated under a standard regimen of pharmacotherapy at an effective dose of drug, and (b) patients who receive the same (reduced) cumulative amount of medication on a continuous schedule of reinforcement as that received by experimental patients treated under a partial schedule of reinforcement, and (c) patients who receive the same dose and frequency of carvedilol as the Partial Reinforcement Group but receive no intervening conditioned stimuli.\n\nIt is possible that a non-continuous schedule of pharmacologic reinforcement (and the concomitant reduced amount of active drug) will exert effects that are indistinguishable from a continuous (standard) regimen of pharmacotherapy (a higher cumulative amount of drug). That outcome or comparison, however, is not critical for evaluating the role of conditioning in the pharmacotherapy of hypertension. Specifically, we will test the hypotheses that:\n\n1. patients treated under a partial schedule of antihypertensive medication will show a greater amelioration of symptoms than that achieved by patients treated with that same (reduced) amount of drug administered under a continuous schedule of reinforcement;\n\n   Conditions permitting, we will also test the predictions that:\n2. irrespective of initial treatment regimen, relapse will occur more quickly following withdrawal of active medication in patients who do not continue to receive conditioned stimuli (placebo) than in patients who continue to receive conditioned stimuli; and\n3. when active drug is withdrawn and replaced by conditioned stimuli alone, resistance to extinction will be greater (i.e., rate of relapse will be less) among patients treated under a partial schedule of reinforcement than patients treated with the same amount of drug administered under a continuous schedule of reinforcement (the partial reinforcement effect).\n\nPositive results would transform the study and practice of pharmacotherapy with respect to placebo effects by providing a new model within which to design treatment protocols for patients with chronic diseases that capitalizes on conditioned pharmacotherapeutic responses. The model, from which testable hypotheses can be derived, also provides a new framework for research on placebo effects and the mechanisms underlying such phenomena."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 44, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "arm 2", "type": "ACTIVE_COMPARATOR", "description": "partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)", "interventionNames": ["Drug: carvedilol"]}, {"label": "arm 3", "type": "ACTIVE_COMPARATOR", "description": "controlled dosing schedule 6.25 mg twice daily (15 days)", "interventionNames": ["Drug: carvedilol"]}, {"label": "arm 4", "type": "ACTIVE_COMPARATOR", "description": "controlled dosing schedule 6.25 mg twice daily, every other day (15 days)", "interventionNames": ["Drug: carvedilol"]}, {"label": "arm 1", "type": "ACTIVE_COMPARATOR", "description": "standard therapy, 25 mg twice daily (15 days)", "interventionNames": ["Drug: carvedilol"]}], "interventions": [{"type": "DRUG", "name": "carvedilol", "armGroupLabels": ["arm 1", "arm 2", "arm 3", "arm 4"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Systolic Blood Pressure", "timeFrame": "day 0"}, {"measure": "Mean Systolic Blood Pressure", "timeFrame": "day 14"}, {"measure": "Mean Systolic Blood Pressure", "timeFrame": "day 30"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* systolic blood pressure between 140-160 mmHG\n* between 18-80 years old\n\nExclusion Criteria:\n\n* abnormal renal function\n* currently pregnant, or trying to become pregnant\n* being treated with a beta-blocker\n* use of illicit drugs", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "John D. Bisognano, M.D., Ph.D.", "affiliation": "University of Rochester", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Rochester", "city": "Rochester", "state": "New York", "zip": "14642", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}]}, "referencesModule": {"references": [{"pmid": "15399519", "type": "BACKGROUND", "citation": "WOLF S. Effects of suggestion and conditioning on the action of chemical agents in human subjects; the pharmacology of placebos. J Clin Invest. 1950 Jan;29(1):100-9. doi: 10.1172/JCI102225. No abstract available."}, {"pmid": "13158365", "type": "BACKGROUND", "citation": "LASAGNA L, MOSTELLER F, VON FELSINGER JM, BEECHER HK. A study of the placebo response. Am J Med. 1954 Jun;16(6):770-9. doi: 10.1016/0002-9343(54)90441-6. No abstract available."}, {"pmid": "14153340", "type": "BACKGROUND", "citation": "KNOWLES JB. CONDITIONING AND THE PLACEBO EFFECT: THE EFFECTS OF DECAFFEINATED COFFEE ON SIMPLE REACTION TIME IN HABITUAL COFFEE DRINKERS. Behav Res Ther. 1963 Aug;1:151-7. doi: 10.1016/0005-7967(63)90018-4. No abstract available."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Partial Reinforcement", "description": "partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)\n\ncarvedilol"}, {"id": "FG001", "title": "Controlled Dosing, Daily", "description": "controlled dosing schedule 6.25 mg twice daily (15 days)\n\ncarvedilol"}, {"id": "FG002", "title": "Controlled Dosing, Every Other Day", "description": "controlled dosing schedule 6.25 mg twice daily, every other day (15 days)\n\ncarvedilol"}, {"id": "FG003", "title": "Standard Therapy", "description": "standard therapy, 25 mg twice daily (15 days)\n\ncarvedilol"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "patient did not follow directions", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Partial Reinforcement", "description": "partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)\n\ncarvedilol"}, {"id": "BG001", "title": "Controlled Dosing, Daily", "description": "controlled dosing schedule 6.25 mg twice daily (15 days)\n\ncarvedilol"}, {"id": "BG002", "title": "Controlled Dosing, Every Other Day", "description": "controlled dosing schedule 6.25 mg twice daily, every other day (15 days)\n\ncarvedilol"}, {"id": "BG003", "title": "Standard Therapy", "description": "standard therapy, 25 mg twice daily (15 days)\n\ncarvedilol"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "14"}, {"groupId": "BG004", "value": "44"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "44.62", "spread": "10.23"}, {"groupId": "BG001", "value": "52.62", "spread": "12.14"}, {"groupId": "BG002", "value": "58.00", "spread": "6.88"}, {"groupId": "BG003", "value": "56.21", "spread": "5.70"}, {"groupId": "BG004", "value": "51.89", "spread": "10.45"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "21"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "23"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "10"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "12"}, {"groupId": "BG004", "value": "29"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "5"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "14"}, {"groupId": "BG004", "value": "44"}]}]}]}, {"title": "Number of participants taking other antihypertensives", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "10"}]}]}]}, {"title": "Mean systolic blood pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "151.59", "spread": "7.22"}, {"groupId": "BG001", "value": "152.64", "spread": "8.95"}, {"groupId": "BG002", "value": "155.42", "spread": "9.62"}, {"groupId": "BG003", "value": "151.88", "spread": "8.19"}, {"groupId": "BG004", "value": "152.34", "spread": "8.05"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Systolic Blood Pressure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "day 0", "groups": [{"id": "OG000", "title": "Partial Reinforcement", "description": "partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)\n\ncarvedilol"}, {"id": "OG001", "title": "Controlled Dosing, Daily", "description": "controlled dosing schedule 6.25 mg twice daily (15 days)\n\ncarvedilol"}, {"id": "OG002", "title": "Controlled Dosing, Every Other Day", "description": "controlled dosing schedule 6.25 mg twice daily, every other day (15 days)\n\ncarvedilol"}, {"id": "OG003", "title": "Standard Therapy", "description": "standard therapy, 25 mg twice daily (15 days)\n\ncarvedilol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "151.59", "spread": "1.92"}, {"groupId": "OG001", "value": "152.64", "spread": "2.38"}, {"groupId": "OG002", "value": "155.42", "spread": "4.17"}, {"groupId": "OG003", "value": "151.74", "spread": "2.05"}]}]}]}, {"type": "PRIMARY", "title": "Mean Systolic Blood Pressure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "day 14", "groups": [{"id": "OG000", "title": "Partial Reinforcement", "description": "partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)\n\ncarvedilol"}, {"id": "OG001", "title": "Controlled Dosing, Daily", "description": "controlled dosing schedule 6.25 mg twice daily (15 days)\n\ncarvedilol"}, {"id": "OG002", "title": "Controlled Dosing, Every Other Day", "description": "controlled dosing schedule 6.25 mg twice daily, every other day (15 days)\n\ncarvedilol"}, {"id": "OG003", "title": "Standard Therapy", "description": "standard therapy, 25 mg twice daily (15 days)\n\ncarvedilol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "133.64", "spread": "2.58"}, {"groupId": "OG001", "value": "132.92", "spread": "3.20"}, {"groupId": "OG002", "value": "133.12", "spread": "3.20"}, {"groupId": "OG003", "value": "135.00", "spread": "2.21"}]}]}]}, {"type": "PRIMARY", "title": "Mean Systolic Blood Pressure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "day 30", "groups": [{"id": "OG000", "title": "Partial Reinforcement", "description": "partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)\n\ncarvedilol"}, {"id": "OG001", "title": "Controlled Dosing, Daily", "description": "controlled dosing schedule 6.25 mg twice daily (15 days)\n\ncarvedilol"}, {"id": "OG002", "title": "Controlled Dosing, Every Other Day", "description": "controlled dosing schedule 6.25 mg twice daily, every other day (15 days)\n\ncarvedilol"}, {"id": "OG003", "title": "Standard Therapy", "description": "standard therapy, 25 mg twice daily (15 days)\n\ncarvedilol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "138.90", "spread": "2.11"}, {"groupId": "OG001", "value": "136.38", "spread": "3.34"}, {"groupId": "OG002", "value": "139.27", "spread": "0.64"}, {"groupId": "OG003", "value": "134.94", "spread": "2.71"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "30 days", "eventGroups": [{"id": "EG000", "title": "Partial Reinforcement", "description": "partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)\n\ncarvedilol", "deathsNumAffected": 0, "deathsNumAtRisk": 13, "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 0, "otherNumAtRisk": 13}, {"id": "EG001", "title": "Controlled Dosing, Daily", "description": "controlled dosing schedule 6.25 mg twice daily (15 days)\n\ncarvedilol", "deathsNumAffected": 0, "deathsNumAtRisk": 13, "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 0, "otherNumAtRisk": 13}, {"id": "EG002", "title": "Controlled Dosing, Every Other Day", "description": "controlled dosing schedule 6.25 mg twice daily, every other day (15 days)\n\ncarvedilol", "deathsNumAffected": 0, "deathsNumAtRisk": 4, "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 0, "otherNumAtRisk": 4}, {"id": "EG003", "title": "Standard Therapy", "description": "standard therapy, 25 mg twice daily (15 days)\n\ncarvedilol", "deathsNumAffected": 0, "deathsNumAtRisk": 14, "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 0, "otherNumAtRisk": 14}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "This study was under enrolled and therefore not powered to answer the hypothesis."}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "John Bisognano", "organization": "University of Rochester", "email": "john_bisognano @ urmc.rochester.edu", "phone": "585-341-7800"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2016-08-03", "uploadDate": "2019-05-21T14:17", "filename": "Prot_SAP_000.pdf", "size": 482501}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2015-03-26", "uploadDate": "2019-05-23T12:03", "filename": "ICF_001.pdf", "size": 189821}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077261", "term": "Carvedilol"}], "ancestors": [{"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "Depressive Disorder", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}